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Expression of alpha-GalNAc glycoproteins by breast cancers
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S_mary The expression of complex carbohydrates recognised by Helix pomatia lectin (HPA, nominal
monosaccharide binding specificity alpha-GalNAc) has been shown to predict unfavourable prognosis in
breast and other cancers. It has been suggested that the prognostic significance of HPA binding may be
through recognition of either Tn epitope (alpha-GaINAc-O-serine threonine) or blood group A antigen
(terminal alpha-l-*3GaINAc attached to the basic H-antigen, Fuc-alpha-l+2-Gal-beta-I-*4(or 3)
GIcNAc-*R). In this study, the expression of glycoproteins terminating in alpha-GalNAc residues was
investigated immunohistochemically using HPA and two monoclonal antibodies - BRIC 66 (anti-alpha-
GalNAc) and BRIC Ill (anti-Tn). In paraffin sections, 74/87 (85%) of breast cancers expressed HPA-binding
ligands, while 28/87 (32%) were positive for BRIC 66 binding and 25187 (29%) expressed Tn. Distribution of
staining patterns were distinctive and different with the three markers. BRIC 66, BRIC Ill and HPA binding
to glycoproteins denrved from breast cancer homogenates and to blood group A and Tn positive glycoproteins
in Western blots confirmed the immunohistochemistry data. The results suggest that the prognostic
significance of HPA binding in breast cancer is unlikely to be simply through recognition of blood group A
antigen or Tn epitope-on cancer cells. Breast cancers may express a complex profile of related but distinct
glycans sharing similar terminal immunodominant sugar GalNAc, which may be implicated in aggressive
biological behaviour.
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Altered glycosylation is a common feature in malignancy.
Alterations in cell-surface carbohydrates have been related to
the metastatic potential of experimental tumours and cor-
related with highly metastatic cell lines (e.g. Ishikawa et al.,
1988; Infusa et al., 1991). We have demonstrated that bin-
ding of a lectin from the Roman snail, Helix pomatia (HPA),
to an unidentified carbohydrate ligand in paraffin sections of
primary breast cancers is strongly associated with metastases
to axillary lymph nodes and distant sites and with conse-
quent poor patient prognosis (Leathem and Brooks, 1987;
Brooks and Leathem, 1991). This observation has been
confirmed by several independent studies on breast cancer
(Fenlon et al., 1987; Fukutomi et al., 1989; Alam et al.,
1990), and recent reports describe similar findings in gastric
cancer (Kakeji et al., 1991), colorectal cancer (Schumacher et
al., 1994) and prostate cancer (Shiraishi et al., 1992).
HPA recognises alpha-glycosidically linked terminal N-ace-
tylgalactosamine (GalNAc) as in, for example, blood group
A, Cad antigens. Forssman determinants (Baker et al., 1983)
and Tn epitope (Springer, 1989). In response to our original
report that HPA binding was associated with poor prognosis
in breast cancer (Leathem and Brooks, 1987), Grundbacher
(1987) argued that the HPA-binding ligand might be blood
group A determinant as an excess of blood group A individ-
uals has been detected in two series of breast cancer patients
(Mourali et al., 1980; Anderson and Hass, 1984). More
recently, Springer (Springer, 1988, 1989) has suggested that
the HPA-binding ligand that appears to be associated with
high metastatic potential and aggressive tumour behaviour
could be Tn epitope. Tn (alpha-GalNAc-O-serine/threonine)
is not normally detectable in healthy tissues, but is frequently
expressed by cancer cells (e.g. Springer et al., 1975, 1985,
1986).
In this study we have examined the expression of glyco-
proteins with terminal non-reducing alpha-GalNAc residues
using two monoclonal antibodies - BRIC 66 (anti-alpha-
GalNAc) and BRIC 111 (anti-Tn) - and the lectin HPA
(nominal monosaccharide specificity alpha-GalNAc).
Mateials and methods
Immunohistochemistrv
Samples, prognostic factors and clinical follow-up Paraffin
sections (5 pm thick) from 87 formalin-fixed routinely pro-
cessed breast cancers were studied. All were cases of
infiltrating ductal carcinoma. All tumours were excised at
University College Hospital, London, during the years 1987
and 1988.
Histopathological identification of tumour types was car-
ried out by a pathologist (AL) on haematoxylin and eosin-
stained sections. Infiltrating cancers were identified as groups
or individual epithelial cells showing pleomorphic, hyper-
chromatic nuclei and frequent nucleoli, variably differentiated
from sheets to tubular structures infiltrating surrounding tis-
sues. In all cases, classification was consistent with that given
in the original pathology report (made by various duty
pathologists) at the time of diagnosis.
Staining protocols
1. HPA. sections were stained for HPA binding by the
indirect avidin-biotin method previously described
(Leathem and Brooks, 1987). As a positive control, a
case known to be strongly positive for HPA binding was
included in each batch for staining. As negative controls,
sections were incubated with lectin in the presence of
0.1 M GalNAc (Sigma).
2. BRIC 111 antibody [specific for the Tn epitope (alpha-
GaINAc-O-SerfThrJ. Tn epitope expression was detected
by a murine monoclonal supernatant BRIC 111 (Interna-
tional Blood Group Reference Laboratory, Bristol). The
antibody is of the IgGI subclass and was produced by
immunising mice with Tn red blood cells. It binds exclus-
ively to erythrocyte Tn glycoproteins but not to
desialised ovine submaxillary glycoprotein and agglu-
tinates Tn red blood cells. The binding site of BRIC 111
may be greater than GaINAc-O-Ser/Thr, probably in-
cluding amino acid residues in juuxtaposition to GalNAc
in Tn glycoprotein (King et al., 1991).
Sections were dewaxed in xylene and rehydrated
through graded alcohols. Endogenous peroxidase activity
was quenched by a 20min incubation with a 1% (v/v)
solution of hydrogen peroxide in methanol. They were
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incubated with the BRIC 111 antibody at a dilution of
1:5 at room temperature overnight. After washing, they
were layered with peroxidase conjugated rabbit anti-
mouse immunoglobulins (Dako) at a dilution of 1:100.
Antibody binding was detected using hydrogen peroxide/
diaminobenzidine. Sections were counterstained with
Mayer's haematoxylin before dehydrating through grad-
ed alcohols and mounting in resinous mountant. All
dilutions and washes were performed in Tris-buffered
saline, pH 7.6
As a positive control sections of a case previously
shown to express the Tn epitope strongly was included.
For negative controls BRIC 111 was (1) omitted or (2)
its binding blocked by incubation in the presence of Tn
glycoproteins (isolated from erythrocytes of a Tn-positive
individual by n-butanol extraction; Anstee and Tanner,
1974) at a concentration of lOOLgml-'.
3. BRIC 66 antibody (specific for alpha-GaINAc). Sections
were stained using BRIC 66 antibody, a murine mono-
clonal IgM supernatant which was produced by immun-
ising mice with ovarian cyst blood group Al glyco-
protein. The antibody is specific for terminal alpha-
GalNAc and it agglutinates both Tn and A red blood
cells. Binding is inhibited by GalNAc, Tn sialoglyco-
proteins and desialised ovine submaxillary glycoprotein.
BRIC 66 reacts immunohistochemically with vascular
endothelium and tumour cells from a group A adenocar-
cinoma (King et al., 1991).
Sections were stained using exactly the same method
as described above for BRIC 111, except that BRIC 66
was used at a dilution of 1:10.
As a positive control a section was included from a
patient known to be of blood group A. For negative
controls, BRIC 66 was (1) omitted or (2) its binding
blocked by 0.1 M GalNAc.
Scoring stained sections Sections were scored as either
'stainers' or 'non-stainers' for HPA, BRIC 111 and BRIC 66
binding according to the criteria we have employed for HPA
binding in previous studies - 'stainers' were cases in which
5% or more of cancer cells were obviously positive or 50%
or more of the cancer cells were very weakly (borderline)
positive; 'non-stainers' were cases in which less than 5% of
the cancer cells were obviously positive or less than 50% very
weakly (borderline) positive (Leathem and Brooks, 1987;
Brooks and Leathem, 1991). In practice, most cases were
either unquestionably positive or completely negative.
Whether endothelium of normal blood vessels and red
blood cells in the vicinity of the tumour were positive or
negative for BRIC 66 and HPA binding was also noted.
Sodiwn dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting
Samples for SDS-PAGE
1. Crude breast cancer homogenates. Ten fresh primary
breast cancers were analysed in this part ofthe study. All
were infiltrating ductal carcinomas. They were not from
the same retrospective series that was analysed by
immunohistochemistry, since fresh tissue was required.
Tumour (1 g) was dissected away from surrounding
breast tissue, minced finely using a scalpel blade, then
homogenised on ice using a Polytron tissue homogeniser.
An equal volume of distilled water was added to each
homogenate. They were spun at 10 000 g for 10 min
using an Eppendorf centrifuge. The aqueous layer was
extracted from between an upper fatty layer and a lower
solid pellet of cell debris.
2. Tn and blood group A glycoproteins. Tn syndrome is a
somatic mutation resulting in a deficiency of beta (1+3)
galactosyltransferase which galactosylates alpha-GaINAc
residues on O-glycans of erythrocytes, lymphocytes,
platelets and granulocytes. Tn and blood group A glyco-
proteins were obtained from the Blood Group Reference
Laboratory in Bnrstol (a generous gift from Dr M-J
King). Tn glycoproteins were extracted from Tn erythro-
cyte membranes (i.e. 'ghosts') with a partition method
using n-butanol (Anstee and Tanner, 1974). Blood group
A glycoproteins were isolated from ovarian cyst fluid by
Dr Winifred M Watkins, Department of Haematology,
Royal Postgraduate Medical School, London, UK.
SDS-PAGE and Western blotting Samples were heated for
I min in a boing water bath in the presence of SDS and the
reducng agent mercaptoethanol. They were loaded at
optimum concentration onto 10% (w/v) acrylamide gels
using the Atto minigel system. The discontinous buffer
system first described by lemmli (1970) was employed. Gels
were run at a steady voltage of 180V for 1 h.
After SDS-PAGE, proteins were transferred to nitrocellu-
lose membrane (Schleicher & Schuell) by semidry electroblot-
ting using a Millipore 'Mil}iblot' system. A constant current
of 2.5 mAcm-2 gel was applied for 30 min.
Immunohistochemistry on blots Blots were stained for bind-
ing of HPA, BRIC 111 and BRIC 66 according to the
following methods:
1. Unreacted sites on the membrane were blocked in a 1%
(w/v) solution of bovine serum albumin (Sigma) for
30 min.
2. They were incubated with HPA-peroxidase (Sigma) at
a concentration of tgml-' overnight, washed, then
incubated with diaminobenzidine-hydrogen peroxide
for Omin.
3. Or BRIC 66 was added at a dilution of 1:10 or BRIC
111 at a dilution of 1:5 overnight, then peroxidase
rabbit anti-mouse immunoglobulins (Dako) 1:100 for
1 h, then diaminobenzidine-hydrogen peroxide for
10min.
All dilutions, washes, etc. were performed using TBS,
pH 7.6, with 0.05% Tween 20 (Sigma). All incubations were
performed with continous agitation on a Luckhams vibrating
platform.
As controls HPA and BRIC 66 were incubated with blots
in the presence of0.1 M GalNAc. BRIC 111 was incubated in
the presence of l0Ijgmli purified Tn glycoproteins.
Resis
Patient characteristics
Patients were followed up from time of diagnosis (1987-88)
until the end of 1993, a maximum period of 6-7 years.
The age range of patients at the time of diagnosis was
22-82 years (mean 57 years). As formal axillary clearance
was not accepted surgical practice at University Colege Hos-
pital during the period 1987-92, axillary node sampling was
performed in only 38/87 (44%) ofpatients. Of these, 14 were
node positive and 24 apparently node negative (for many
patients, only a small number of nodes - as few as one node
- was sampled, casting doubt on the accuracy of this stag-
ing). Tumour size ranged from 0.8 to 5 cm (mean 2.6cm).
ABO blood group was known for 31/87 patients: 15 were
blood group A, one was group AB, four were group B and
11 were group 0.
Immunohistochemistry
The expressions of Tn epitope as detected by BRIC 111,
alpha-GalNAc detected by BRIC 66, and HPA-binding
ligands are summarised in Table I. Eighty-five per cent were
HPA positive, 32% were BRIC 66 positive and 29% were
BRIC 111 positive.
Staining of cancer cells with all three markers was clean,
highly selective and dramatically intense. The staining pat-
terns with HPA, BRIC 66 and BRIC 111 were distinctive
and different. Enxamples of staining patterns observed with
the three markers on the same area in serial sections of one
cancer are given in Figure la-c.




BRIC 66 28 (32%) 59 (68%)
BRIC 111 25 (29%) 62 (71%)
HPA 74 (85%) 13 (15%)
Normal endothelium staining
BRIC 66 33 (38%) 54 (62%)







Figwe I Comparison of pattern and distribution of the binding
of (a) BRIC 111 for Tn epitope, (b) BRIC 66 for alpha-GaINAc
and (c) HPA for GaINAc-related glycoconjugates to the same
area of breast cancer in serial paraffin setions.
Ga6Mglyoprinsandbita- raxP
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BRIC 111 binding to breast cancers BRIC 111 staining re-
vealed that the Tn epitope was very limited in its distribu-
tion. Most (71%) sections were negative. Staining was
generally localised to a small proportion, typically <20%, of
cancer cells. Where staining did occur, however, it was
intense and dramatic. Individual cancer cells or small islands
of cancer cells were strongly positive within the otherwise
negative tumour mass. Staining was localised at luminal sur-
faces within the tumour mass, and in intensely staining foci
within the cancer cell cytoplasm. An example of BRIC 111
staining to detect Tn epitope is given in Figure la. Normal
breast ducts and foci of benign breast disease were con-
sistently negative for BRIC 111 staining.
BRIC 66 binding to breast cancers BRIC 66 showed a quite
distinct pattern of distribution, even though the proportion
of cases considered to be positive with the two antibodies
was similar (BRIC 66 stained cancer cells in 32% of cases,
compared with 29% with BRIC 111). Finely granular and
amorphous cytoplasmic staining was seen, with concentration
at luminal surfaces. An interesting and unique feature was
the presence of scattered linear concentrations of staining
polarised towards the edges of some cancer cells. BRIC 66
also bound to glycoproteins on some normal structures,
notably the luminal surface of some normal breast ducts and
to some areas ofbenign breast disease (including hyperplasia,
apocrine metaplasia and the walls of some cysts).
BRIC 66 binding to endotheliwn Of the 31 patients for
whom blood group was known, 16 were of blood group A or
AB; all but one of these (a group A+ individual) showed
endothelial/red blood cell positivity with BRIC 66. In all
known blood group B and 0 patients, endothelium and red
blood cells were negative for BRIC 66 binding. These data
illustrate a good correlation between patient blood group and
detection of blood group A antigen on endothelium and red
blood cells by the BRIC 66 antibody.
HPA binding to breast cancers HPA binds much more wide-
ly to the tumour cells than does either antibody, and this was
reflected in staining pattern and distribution. Eighty-five per
cent of cancers were positive for HPA binding, and, in
positive cases, most cancer cells stained, and staining was
intense (Figure lc). Cytoplasmic staining with HPA was far
denser than with either monoclonal antibody and luminal
surface localisation more marked. The overwhelming pattern
was one of granular cytoplasmic staining with cell border
localisation. HPA, like BRIC 66, bound selectively to the
luminal surface of some normal breast ducts and to some
foci of benign breast disease.
HPA binding to endotheliwn In the 33/87 (38%) cases posi-
tive with BRIC 66, HPA also bound to endothelium ofblood
vessels and to red blood cells.
Relationship of endothelial staining and cancer cell staining
Cancer cell expression of glycoconjugates recognised by
BRIC 66 and HPA was unrelated to known blood group or
endothelial staining with the two markers.
Western blots
BRIC 66, BRIC 111 and HPA binding to glycoproteins from
breast cancers and from blood group A- and Tn-positive
erythrocytes supported the immunohistochemistry data.
BRIC 111 binding was highly selective to Tn glycoproteins
only. BRIC 66 and HPA recognised a wider range of Gal-
NAc glycoproteins.
BRIC 66, BRIC 111 and HPA binding to breast cancer glyco-
proteins Typical examples of the results obtained for BRIC
66, BRIC 111 and HPA binding to homogenates of primary
breast cancers are given in Figure 2a. BRIC 111 (lanes 4 and
7 of Figure 2a) did not bind to any of the bands in any
tumour extract analysed, although it did give positive stain-Gac gycopriisuW hrana caner
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ing of dot blots of around 30% of whole tumour extracts.
We interpret these results as indicating that Tn is expressed
on proteins of either too high or too low a molecular weight
to be visualised on our gel system (i.e. under reducing condi-
tions, outside the approximately 20-120 kDa range). HPA
(Figure 2a, lanes 2 and 5) and BRIC 66 (Figure 2a, lanes 3
and 6) both bound several glycoprotein bands: some were
identical (for example, in lanes 5 and 6 of Figure 2a, at least
six discrete shared bands are seen in the lower molecular
weight region up to -40 kDa; three strong shared bands are
apparent in the 48.5-58 kDa region), although it was clear
that both HPA and BRIC 66 each recognised many unique
species.
Both BRIC 66 and HPA binding to blots could be inhibit-
ed by incubation in the presence of 0.1 M GalNAc.







b 1 2 3 4 5 6 7
BRIC 66, BRIC 111 and HPA binding to Tn and blood group
A glycoproteins Figure 2b illustrates HPA, BRIC 111 and
BRIC 66 binding to Tn and blood group A glycoproteins.
(Tn glycoproteins were run in lanes 2-4, and blood group A
glycoproteins in lanes 5-7.)
BRIC 111, as expected, did not react with any normal
blood group A glycoprotein (Figure 2b, lane 7). BRIC 66
(Figure 2b, lane 5) gave strong labelling of bands ranging in
molecular weight from around 35 to 116 kDa. HPA (Figure
2b, lane 6) produced a stronger staining pattern, labelling
bands over the full molecular weight range analysed (approx-
imately 20-120 kDa). Major membrane glycoproteins known
to carry ABH determinants appeared to be labelled by BRIC
66 binding- band 3 (Mr95 K, marked C) and band 4.5
(Mr 55 K, marked E) which carry polylactosaminoglycans
were tentatively identified from their approximate molecular
weight and their characteristic broad, diffuse bands (a feature
of heterogeneity of glycosylation) (Hakomori, 1981) and the
region corresponding to polyglycosylceramide (Mr 30 K,
marked E) was tentatively identified by its approximate
molecular weight (Fukuda et al., 1984).
BRIC 111 labelled two major Tn-positive bands in
immunoblot (Figure 2b, lane 4) which correspond to glyco-
phorin A monomer (M, -43 K, band marked A) and glyco-
phorin B monomer (Mr -26 K, band marked B), in addition
to several less prominent bands lying between them. HPA
(Figure 2b, lane 3) recognised some, but intriguingly not all,
of the bands recognised by BRIC 111, and seemed to
preferentially label those falling in the 40-80 kDa molecular
weight range. BRIC 66 (Figure 2b, lane 2) staining was
stronger and revealed more bands than HPA. BRIC 66 also
recognised some, but not all, of the Tn positive bands, and
these seemed to be mostly different species from those
labelled by HPA, falling largely in the 20-40 kDa molecular
weight range.
The Tn glycoprotein completely inhibited binding of HPA,
BRIC 66 and BRIC 111 to Tn-positive lanes, but had no
effect on HPA or BRIC 66 binding to blood group A.
GalNAc at 0.1 M inhibited binding of BRIC 66 and HPA to
both Tn and blood group A lanes, but was ineffective in











Fugwe 2 Western blots of SDS-PAGE sparations. (a) Breast
cancer glycoproteins from two separate cancers (first cancer, lanes
2-4; second cancer, lanes 5-8) probed for binding of HPA (lanes
2 and 5), BRIC 66 (lanes 3 and 6) and BRIC 111 (lanes 4 and 7).
Lane 1, molecular weight standards (molecular weights are given
in klDa); lane 8, control - first antibody or lectin omitted. (b) Tn
(lanes 2-5) and blood group A (lanes 5-7) glycoproteins probed
for binding of BRIC 66 (lanes 2 and 5), HPA (lanes 3 and 6) and
BRIC 111 (lanes 4 and 7). Lane 1, molecular weight standards
(molecular weights are given in kDa). Band marked A is
glycophorin A monomer and band B is glycophorin B monomer
- major Tn-related glycophorin bands. Broad streaky bands C
and D are poly-N-acetyllactosaminoglycans, and E is polyg-
lycosylcramide - major membrane glycoconjugates known to
carry ABH determinants.
Several studies have confirmed that expression of HPA-bind-
ing glycoconjugates by breast cancer (Fenlon et al., 1987;
Leathem and Brooks, 1987; Fukutomi et al., 1989; Alam et
al., 1990; Brooks and Leathem, 1991), gastric cancer (Kakeji
et al., 1991), colorectal cancer (Schumacher et al., 1994) and
prostate cancer (Shiraishi et al., 1992) is associated with both
local and distant metastases and consequently poor prog-
nosis. We have postulated that a group of as yet unidentified,
HPA-binding, abnormally glycosylated molecules bearing ter-
minal GalNAc moieties may act as biological markers of
aggressive cancer behaviour (Brooks and Leathem, 1991).
The abelrant expression of blood group antigens by
cancers has been linked in several studies to prognosis (e.g.
Idikio and Manickavel, 1991; Lee et al., 1991), as has expres-
sion of Tn antigen (Springer, 1988; Springer et al., 1990).
Springer (1988, 1989) has suggested that the predominant
structure recognised by HPA in breast (and other) cancers
encompasses the Tn epitope, and that it is Tn which is
responsible for the prognostic sigificance of HPA binding.
Grundbacher (1987) has suggested that it is blood group A
antigen.
The utility of HPA as a probe for detection of terminal
non-reducing N-acetyl-alpha galactosaminyl end groups such
as blood group A (for example, Hammastrom and Kabat,
1969) and Tn epitope (for example Cartron and Nurden,
1979; Springer, 1989) is well established. It is no surprise,
therefore, that HPA recognises both blood group A deter-
minant and the Tn epitope if they are expressed by cancer
cells. However, to view HPA as specific simply for the
monosaccharide alpha-GalNAc is naive, and it is of criticalGaNk - o andhm cance
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importance to understand that the actual binding site of the
lectin encompasses terminal and subterminal sugars and that
the overall spatial arrangement of molecules also plays a
crucial role in determining binding characteristics (Baker et
al., 1983).
That HPA binds more than just alpha-GalNAc in breast
cancers is illustrated both by the proportion of cancers posi-
tive by immunohistochemistry with the three markers (85%
of cases were HPA positive, compared with 32% BRIC66/
alpha-GalNAc positive and 29% BRIC 111/Tn positive) and
the differences in staining patterns observed (HPA recognised
complex sugars on a greater number of cancers and on a
greater proportion of cancer cells within any individual
tumour). The HPA binding to 85% of cancers closely reflects
the clinical recurrence rate of these cancers. Western blotting
results also illustrate the complex profile of glycans recog-
nised by the monoclonal antibodies and HPA. These results
suggest that the prognostic significance of HPA binding in
breast cancer is unlikely to be simply through recognition of
terminal alpha-GalNAc as in blood group A substance or Tn
alone, but through binding to a more broader profile of
related GalNAc-type glycans.
An interesting feature of the immunohistochemical staining
was that BRIC 66 and HPA bound to endothelium of nor-
mal blood vessels and to erythrocytes in some (29/87 or
33%) of cases. As this correlated well with known patient
ABO blood group, it was assumed that HPA and BRIC 66
were recognising the terminal GalNAc of blood group A
determinant in group A and AB patients (King et al., 1991).
There was no relationship between positivity ofendothelium1
erythrocytes and positivity of cancer cells in the same cases,
i.e. cancer cells were frequently positive for BRIC 66/HPA
while endothelium and red blood cells were negative and vice
versa.
Formal life table analyses did not seem appropriate in this
study, owing to the small number of patients studied, but
very preliminary analysis of immunohistochemistry data and
clinical/prognostic parameters yielded promising results in
that node-positive cancers and those in which metastatic
disease became apparent before the end of the follow-up
period were more likely to be positive for expression of
alpha-GalNAc glycans. Tn appears to be a functional marker
of aggressive cancer behaviour possibly through its role as a
cell adhesion molecule, attaching cancer cells to normal cells,
in metastasis (Springer et al., 1990). The relationship between
HPA binding to cancers and aggressive biological behaviour
may be, in part, through recognition of terminal alpha-
GalNAc on the Tn epitope. However, HPA does appear to
be detecting other related ligands which share similar ter-
minal glycans and which also may be involved, perhaps as
cell adhesion molecules, in cancer metastasis. Although Tn
may be associated with aggressive behaviour, it is only
detectable in a minority of aggressive cancers. It seems more
likely to be the GalNAc group, linked to a larger glycan (and
probably not blood group A). that is associated with cancer
progression.
Detailed analysis of the structure and precise function of
these moieties is under intensive investigation in our labor-
atory. HPA reactivity of breast cancers has recently been
positively correlated with amplification of the c-myc proto-
oncogene (Fukutomi et al., 1989), highlighting an intriguing
relationship between oncogenic activity and expression of a
group of aberrant GalNAc glycoconjugates which seem to be
intimately involved in aggressive cancer behaviour.
AcknowledI Its
The authors thank Dr May-Jean King of the International Blood
Group Reference Laboratory. Bristol, for her gift of Tn glycoprotein
and blood group A ovarian cyst glycoproteins and for invaluable
help and advice during the course of this study. This work was
supported by a grant from Action against Breast Cancer.
Referces
ALAM SM. WHITFORD P. CUSHLEY W. GEORGE WD AND CAMP-
BELL AM. (1990). Flow cytometric analysis of cell surface carbo-
hydrates in metastatic human breast cancer. Br. J. Cancer, 62,
238-242.
ANDERSON DE AND HASS C. (1984). Blood type A and familial
breast cancer. Cancer, 54, 1845-1849.
ANSTEE DJ AND TANNER MJA. (1974). The distribution of blood
group antigens on butanol extraction of human erythrocyte
'ghosts'. Biochem J., 138, 381-386.
BAKER DA, SUGII S. KABAT EA. RATCLIFFE RM, HERMENTIN P
AND LIEMIEUX RU. (1983). Immunochemical studies on the
combining sites of Forssman hapten reactive hemagglutinins from
Dolichos biflorus, HeliL pomatia, and Wisteria floribunda. Bio-
chemistrn, 22, 2741-2750.
BROOKS SA AND LEATHEM AJC. (1991). Prediction of lymph node
involvement in breast cancer by detection of altered glycosylation
in the primary tumour. Lancet, 338, 71-74.
CARTRON JP AND NURDEN AT. (1979). Galactosyltransferase and
membrane glycoprotein abnormality in human platelets from Tn
syndrome donors. Nature. 282, 621-623.
FENLON S. ELLIS 10. BELL J, TODD IH. ELSTON CW AND BLAMEY
RW. (1987). Helix pomatia and Ulex europeaus lectin binding in
human breast carcinoma. J. Pathol., 152, 169-176.
FUKUDA MN. PAPAYANNOPOULOU T, GORDON-SMITH EC. ROC-
HANTS H AND TESTA U. (1984). Defect in glycosylation of
erythrocyte membrane proteins in congenital dyserythropoietic
anaemia type II (HEMPAS). Br. J. Haematol., 56, 55-68.
FUKUTOMI T. ITABASHI M. TSUANE S. YAMAMOTO H. NANA-
SAWA T AND HIROTO T. (1989). Prognostic contributions of
Helix pomatia and carcinoembryonic antigen staining using his-
tochemical techniques in breast carcinomas. Jpn J. Clin. Oncol.,
19, 127-134.
GRUNDBACHER FJ. (1987). Helix pomatia lectin binding and predic-
tive value on breast cancer (letter). Lancet, 1145.
HAKOMORI S. (1981). Blood group ABH and Ii antigens of human
erythrocytes: chemistry. polymorphism and their developmental
change. Semin. Hematol.. 18, 39-62.
HAMMASTROM S AND KABAT EA. (1969). Purification and charac-
terisation of a blood group A reactive haemagglutinin from the
snail Helix pomatia and a study of its combining site. Biochemis-
try, 8, 2696-2705.
LDIKIO HA AND MANICKAVEL V. (1991). Correlation of blood
group antigen expression and oncogene related proteins in malig-
nant prostatic tissues. Pathol. Res. Pract., 187 (2-3). 189-
197.
INFUSA H. KOJIMA N. YASUTOMI M AND HAKOMORI S. (1991).
Human lung adenocarcinoma cell lines with different lung colon-
ization potential (LCP), and a correlation between expression of
sialosyl dimeric Le(X) (defined by MAB FH6) and LCP. Clin.
Exp. Metastasis, 9 (3), 245-257.
ISHIKAWA M. DENNIS IW. MAN S AND KERBEL RS. (1988). Isola-
tion and characterisation of spontaneous wheat germ agglutinin-
resistant human melanoma mutants displaying remarkably
different metastatic profiles in nude mice. Cancer Res., 48 (3),
665-670.
KAKEJI Y. TSUJITANI S. MORI M. MAEHARA Y AND SUGIMACHI
K. (1991). Helix pomatia agglutinin binding activity is a predictor
of survival time for patients with gastric carcinoma. Cancer, 68,
2438-2442.
KING M-J. PARSONS SF. WU AM AND JONES M. (1991). Immuno-
chemical studies of the differential binding properties of two
monoclonal antibodies reacting with Tn red cells. Transfusion, 31
(2), 142-149.
LAEMMLI UK. (1970). Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature, 227, 680-
685.
LEATHEM AJ AND BROOKS SA. (1987). Predictive value of lectin
binding on breast cancer recurrence and survival. Lancet, i
1054-1056.
LEE JS. RO JY. SAHIN AA. HONG WK. BROWN BW. MOUNTAIN CF
AND HITTELMAN WN. (1991). Expression of blood group anti-
gen A - a favourable prognostic factor in non small cell lung
cancer. N. Engl. J. Med., 324, 1084-1090.Gxic - kid t caw
SA Brooks and AJC Leaiem
1 QT
MOURALI N, MUENZ LR, TABBANE F, BELHASSEN S, BAHI J AND
LEVINE PH. (1980). Epidemiologic features of rapidly progresing
breast cancer in Tunisia. Cancer, 46, 2741-2746.
SCHUMACHER U. RIGGS D, LOIZIDOU M, PICKERING R,
LEATHEM A AND TAYLOR 1. (1994). Helix pomatia agglutinin
binding is a useful prognostic indicator in colorectal cancer.
Cancer, 74, 3104-3107.
SHIRAISHI T. AT'SUMI S AND YATANI R. (1992). Comparative study
of prostatic carcinoma bone metastasis among Japanese in Japan
and Japanese Americans and whites in Hawaii. Adv. Exp. Med.
Biol., 324, 7-16.
SPRINGER GF. (1988). Tn epitope density predicts aggressiveness of
primary breast carcinoma (abstract). Proc. Annu. Meet. Am.
Assoc. Cancer Res., 29, A785.
SPRINGER GF. (1989). Tn epitope (N-Acetyl-D-galactosamine-alpha-
0-serine/threonine) density in primary breast carcinoma. A func-
tional predictor of aggressiveness. Mol. Immwuol., 26, 1-5.
SPRINGER GF. DESAI PR AND BANATWALA 1. (1975). Blood group
MN antigens and precursors in normal and malignant human
breast glandular tissue. J. Natl Cancer Inst., 54, 335-339.
SPRINGER GF, TAYLOR CR, HOWARD DR, TEGTMEYER H, DESAI
PR, MURTHY MS, FELDER B AND SCANLON EF. (1985). Tn, a
carcinoma-associated antigen, reacts with anti-Tn of normal
human sera. Cancer, 55, 561-569.
SPRINGER GF, DESAI PR. ROBINSON MK. TEGTMEYER H AND
SCANLON EF. (1986). The findamental and diagnostic role of T
and Tn antigens in breast carcinoma at the earliest histologic
stage and throughout. In Twnour Markers and their Signficance
in the Management of Breast Cancer, Progress in Clinical and
Biological Research. Vol. 204, Dao TL, Brodie A and Ip C (eds)
pp. 47-70. A US National Cancer Institution Publication, Alan
R Liss: New York.
SPRINGER GF, WISE W, CARLSTEDT SC, DESAI PR, TEGTMEYER
H, STEIN R AND SCANLON EF. (1990). Pancarcinoma T and Tn
epitopes: autoimmunogens and diagnostic markers that reveal
incpient carcinomas and help establish prognosis. ImmunoL. Ser.,
53, 587-612.